![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_t2UVAyRQ0KAmAyoMUVfPgvSJGgKyMTim31Al-yehzlT80J-kNA1QAiIbyH0ZJo64xLJE0k-k-ya8E09t-duRXHl5549ddXrIiOqAGw-V8=s0-d){kind=small}
Public release date: 30-Jan-2013[ | E-mail |
Share ] Contact: Jeremy Craig
404-413-1357
Georgia State University
ATLANTA Sang-Moo Kang, associate professor at Georgia State University's Center for Inflammation, Immunity and Infection, has received a federal five-year, $3.4 million grant to bolster research that will lead to better flu vaccines and vaccines against respiratory syncytial virus (RSV), a disease for which there is no immunization.
The grant from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases will aid Kang's research in developing a virus-like particle, or VLP, vaccine technology.
VLPs mimic viruses, but are non-infectious, which allows for safer vaccines, especially for young children, elderly people and patients whose immune systems are compromised. VLPs trigger the immune system to respond, leading to immunity in the same way that regular vaccines made with whole viruses act.
"VLPs are a result of new technology using recombinant genetic engineering," Kang said. "VLP technology can manipulate pathogens in a safe way so that we can design a vaccine mimicking the shape and structure of a virus.
"A VLP is an empty particle without the genetic information of a pathogen, thus highlighting its safety."
The potential of this research could lead to not only better vaccines for influenza, which is potentially deadly in some patients and which has led to deaths during this year's flu season, but also RSV.
RSV is a respiratory virus that infects the lungs and breathing passages. Most healthy people can recover from RSV infection in one to two weeks, but infections can be severe in young children, infants and older adults.
According to the Centers for Disease Control and Prevention, about 75,000 to 125,000 hospitalizations related to RSV occur among children under one year old, and RSV infection results in about 1.5 million outpatient medical visits among children under the age of five.
Kang's lab will test VLP technology and ways to deliver the vaccines without long needles, such as nasal delivery, microneedles and oral vaccination.
###
An abstract of the grant, 1R01AI105170-01, is available at the NIH's Project RePORTer website, http://projectreporter.nih.gov, or is available upon request from Georgia State 's Public Relations and Marketing Communications office.
For more about Kang, visit http://inflammation.gsu.edu/skang.html.
For more about the Center for Inflammation, Immunity and Infection, visit http://inflammation.gsu.edu.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 30-Jan-2013[ | E-mail |
Share ] Contact: Jeremy Craig
404-413-1357
Georgia State University
ATLANTA Sang-Moo Kang, associate professor at Georgia State University's Center for Inflammation, Immunity and Infection, has received a federal five-year, $3.4 million grant to bolster research that will lead to better flu vaccines and vaccines against respiratory syncytial virus (RSV), a disease for which there is no immunization.
The grant from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases will aid Kang's research in developing a virus-like particle, or VLP, vaccine technology.
VLPs mimic viruses, but are non-infectious, which allows for safer vaccines, especially for young children, elderly people and patients whose immune systems are compromised. VLPs trigger the immune system to respond, leading to immunity in the same way that regular vaccines made with whole viruses act.
"VLPs are a result of new technology using recombinant genetic engineering," Kang said. "VLP technology can manipulate pathogens in a safe way so that we can design a vaccine mimicking the shape and structure of a virus.
"A VLP is an empty particle without the genetic information of a pathogen, thus highlighting its safety."
The potential of this research could lead to not only better vaccines for influenza, which is potentially deadly in some patients and which has led to deaths during this year's flu season, but also RSV.
RSV is a respiratory virus that infects the lungs and breathing passages. Most healthy people can recover from RSV infection in one to two weeks, but infections can be severe in young children, infants and older adults.
According to the Centers for Disease Control and Prevention, about 75,000 to 125,000 hospitalizations related to RSV occur among children under one year old, and RSV infection results in about 1.5 million outpatient medical visits among children under the age of five.
Kang's lab will test VLP technology and ways to deliver the vaccines without long needles, such as nasal delivery, microneedles and oral vaccination.
###
An abstract of the grant, 1R01AI105170-01, is available at the NIH's Project RePORTer website, http://projectreporter.nih.gov, or is available upon request from Georgia State 's Public Relations and Marketing Communications office.
For more about Kang, visit http://inflammation.gsu.edu/skang.html.
For more about the Center for Inflammation, Immunity and Infection, visit http://inflammation.gsu.edu.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-01/gsu-gsr013013.php
nike nfl jerseys katie couric barista university of kentucky ncaa oakland news alec baldwin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.